SCYX
SCYX
NASDAQ · Pharmaceuticals

Scynexis Inc

$3.45
+0.15 (+4.55%)
Financial Highlights (FY 2026)
Revenue
33.36M
Net Income
-13,940,184
Gross Margin
100.0%
Profit Margin
-41.8%
Rev Growth
+59.4%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 100.0% 100.0% 42.8% 42.8%
Operating Margin -78.0% -70.2% 27.4% 27.9%
Profit Margin -41.8% -39.7% 28.0% 22.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 33.36M 20.93M 9.68M 11.00M
Gross Profit 33.36M 20.93M 4.14M 4.71M
Operating Income -26,029,406 -14,700,342 2.65M 3.07M
Net Income -13,940,184 -7,872,844 2.71M 2.47M
Gross Margin 100.0% 100.0% 42.8% 42.8%
Operating Margin -78.0% -70.2% 27.4% 27.9%
Profit Margin -41.8% -39.7% 28.0% 22.5%
Rev Growth +59.4% +59.4% +15.5% +17.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 3.72M 4.09M
Total Equity — — 23.32M 24.16M
D/E Ratio — — 0.16 0.17
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -26,027,808 -15,516,075 3.39M 3.79M
Free Cash Flow — — 1.90M 2.29M